DCL0024 · Research use only
A1I4R13C18-2 · Datasheet
A1I4R13C18-2 is a cationic / ionizable lipid disclosed in WO2023142167A1 for nucleic-acid delivery research. Its structure contains two linoleoyl chains and azepan-1-ylethyl substituents on a bis-amide scaffold. In the patent’s intravenous luciferase-mRNA screen in C57BL/6 mice, the A1I4R13C18-2 formulation gave a splenic luminescence reading of 2.85 × 10⁴ at the 6-hour endpoint. The study used a four-component formulation containing the test lipid, cholesterol, DSPC and DMG-PEG. This result supports investigation of spleen-associated mRNA expression; organ selectivity and product-specific safety were not established by this table.
| Parameter | Specification |
|---|---|
| CAS No. | Not available |
| Chemical Name | A1I4R13C18-2 |
| Synonyms | A1I4R13C18 2; A1I4R13C182 |
| SMILES | CCCCC/C=C\C/C=C\CCCCCCCC(=O)N(CCN1CCCCCC1)C(C(=O)NCCN(C)CCNC(=O)C(C(C)C)N(CCN1CCCCCC1)C(=O)CCCCCCC/C=C\C/C=C\CCCCC)C(C)C |
| Formula | C67H123N7O4 |
| M.Wt | 1090.77 |
| Purity | >95% by ELSD-HPLC |
| Storage | Refer to the supplied batch label and documentation. |
| Shipping condition | Contact us for current shipping conditions. |
| Publication | WO2023142167A1 (2023) |
References
- Liu Z, Chen Y, He Z, Yue Z. Cationic lipid analog, and composition and use thereof. WO2023142167A1. Applicant: Guangzhou Lide Biomedicine Technology Co Ltd. Published 3 August 2023. Read the original patent. Compound identities: Example 2 and Table 3; formulation: Example 6 (printed page 19); intravenous mouse study: Example 10 (printed page 20), Table 3 (printed page 27). Printed page numbers refer to the supplied publication; PDF pages are two pages higher.